Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels

BEDMINSTER, NJ and DUBLIN, IRELAND --(Marketwired - May 20, 2016) - Amarin Corporation plc ( NASDAQ : AMRN ) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels.

The poster (#164), titled "Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women With Very High Triglyceride Levels: Results From the MARINE Study," was presented on May 20, 2016. Researchers observed that compared to placebo, Vascepa administered at 4 g/day significantly reduced triglyceride (TG), non-HDL-C, and total cholesterol (TC) levels without increasing LDL ("bad") cholesterol in women with very high TG levels (≥500 and ≤2000 mg/dL). The analysis was led by Lori Mosca, MD, MPH, PhD, Professor of Medicine Emerita and Center Director of the American Heart Association Go Red for Women Research Network at Columbia University Medical Center, New York.

"It is important to generate data that address the specific needs of women, especially in fields where the data could prove useful to patient care," said Dr. Mosca. "The findings presented today, although taken from a small study sample population of women, are encouraging because the efficacy and safety of Vascepa 4 g/day were consistent with the overall MARINE results, which included 229 patients. It is vitally important to evaluate both potential benefits and side effects of therapies in women and not assume results from men are similar in women."

The clinical implications of lowering triglycerides with Vascepa 4 g/day are being investigated in the REDUCE-IT cardiovascular outcomes study of statin-treated women and men with persistent elevated TG levels.

The MARINE study and post-hoc analysis were sponsored by Amarin and were not affiliated with or funded by the American Heart Association (AHA) or the AHA Go Red for Women Research Network.

About the Presented Research

Dr. Mosca's analysis was based on a subgroup of 36 women in the MARINE trial, a study designed to determine the effects of pure EPA prescription therapy (Vascepa) on patients with severe hypertriglyceridemia, including those who were also receiving statin therapy. The 12-week, double-blind, phase 3 MARINE trial included patients (n=229) with TGs between 500 mg/dL and 2000 mg/dL. Statin treatment was not mandated as part of the study's inclusion criteria, but was used as a stratification factor. The subgroup analysis presented at NLA evaluated the efficacy of Vascepa on TG levels, lipid and lipoprotein parameters, and EPA concentrations among the subgroup of women (92% white, mean age 59 years) that were receiving either Vascepa 4 g/day (n=18; 6 on statins) or placebo (n=18; 3 on statins).

The analysis showed that, compared to placebo, Vascepa significantly reduced TGs (−23%; P=0.03), non-high-density lipoprotein cholesterol (−16%; P=0.008), and total cholesterol (−15%; P=0.002) levels without an increase in LDL-C levels (−12%; P> 0.05).

As with many subgroup analyses, a limitation is the small sample size, but the results are nonetheless suggestive of complementary beneficial changes in TG levels and lipid and lipoprotein parameters compared with placebo. The efficacy and safety of Vascepa 4 g/day in women were consistent with the overall MARINE results.

Amarin's clinical development program for Vascepa includes a trial known as REDUCE-IT, the first multinational cardiovascular outcomes study evaluating the benefit of pure EPA therapy or any triglyceride lowering therapy as an add-on to statins in patients with high cardiovascular risk who, despite stable statin therapy, have elevated triglyceride levels (200-499 mg/dL). Amarin recently announced that it has achieved its target enrollment of 8,000 patients for the trial and that an interim efficacy analysis by the independent Data Monitoring Committee of the REDUCE-IT trial is expected in September or October 2016.

Additional information on MARINE, REDUCE-IT and Amarin's other clinical studies of Vascepa can be found at www.clinicaltrials.gov .

About VASCEPA ®  (icosapent ethyl) capsules

VASCEPA ®  (icosapent ethyl) capsules are a single-molecule prescription product consisting of 1 gram of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa is known in scientific literature as AMR101.

FDA-approved Indication and Usage

  • VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
  • The effect of VASCEPA on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information for VASCEPA

  • VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
  • Use with caution in patients with known hypersensitivity to fish and/or shellfish.
  • The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction > 3% and greater than placebo.
  • Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
  • In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
  • Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.
  • Adverse events and product complaints may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT  WWW.VASCEPA.COM .

Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to the ongoing REDUCE-IT cardiovascular outcomes study. Vascepa ®  (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com . For more information about Amarin, visit  www.amarincorp.com .

Forward-looking statements

This press release contains forward-looking statements, including statements about the potential efficacy and therapeutic benefits of Vascepa and EPA, including implications about the potential clinical importance of the findings presented. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with retrospective sub-set analyses, research on biomarkers thought to be relevant in the treatment of cardiovascular disease, research and development and clinical trial risk generally, including the risk that study results in small sample sizes may not be predictive of future results in larger studies and that studied parameters may not have clinically meaningful effect. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and the public using our company website ( www.amarincorp.com ), our investor relations website ( http://www.amarincorp.com/investor-splash.html ), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information:   Investor Relations:   Kathryn McNeil  Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com Lee M. Stern Trout Group  In U.S.: +1 (646) 378-2922 lstern@troutgroup.com Media Inquiries: Ovidio Torres Finn Partners In U.S.: +1 (312) 329 3911 Ovidio.torres@finnpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 42

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 174

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 15

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 203

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 22

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 15

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 282

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

BIEL Crystal's Innovative Smartphone Glass Cover Revolutionizes Durability

Updated Category News Views 299

BIEL Crystal's Innovative Smartphone Glass Cover BIEL Crystal, a notable supplier for Apple and a leader in smart device components, has recently introduced its cutting-edge product, the "Witch Cloak." This ultra-hard coating smartphone glass cover represents a significant advancement in the technology used to protect smartphones from daily wear and tear, notably featured...

Continue Reading
Covenant Clearinghouse Triumphs in Legal Battle with Chicago Title

Updated Category News Views 780

Covenant Clearinghouse Triumphs in Legal Battle Covenant Clearinghouse recently achieved a significant legal victory against the Chicago Title Company, concluding a complex litigation case. The case, documented as Chicago Title Ins. Co. v. Covenant Clearinghouse, LLC, revolved around crucial property rights under the Illinois Transfer Fee Covenant Act. Legal Proceedings...

Continue Reading
TTEC CEO's Buyout Proposal: What It Means for Stakeholders

Updated Category News Views 137

TTEC's CEO Buyout Proposal: Evaluating the Future TTEC Holdings, Inc. (NASDAQ: TTEC), known for its AI-driven customer experience solutions, is currently assessing a buyout proposal presented by its CEO, Kenneth Tuchman. This significant move has prompted the company to engage the services of Rothschild & Co as its financial advisor, alongside legal support from Skadden,...

Continue Reading
Primech AI Unveils HYTRON LITE Bathroom Cleaning Solution

Updated Category News Views 167

Primech AI Launches Innovative HYTRON LITE at Industry Event Primech AI Pte. Ltd. (Nasdaq: PMEC) is making waves in the robotics industry with its latest innovative creation, the HYTRON LITE bathroom cleaning robot, introduced during a significant event focused on facilities management. This gathering, that united key players, took place at Temasek Polytechnic and was...

Continue Reading
The Growth Journey of Travelers Companies: A Five-Year Analysis

Updated Category News Views 255

Understanding Travelers Companies' Market Performance When evaluating the potential return on investment in stocks, it's essential to look at the historical performance of companies like Travelers Companies (NYSE: TRV). This prominent insurance provider has shown remarkable consistency and growth over the years, recently achieving a market capitalization of $63.96...

Continue Reading